Skip to main content

Ocriplasmin Recommended for Vitreomacular Adhesions


July 27, 2012 — An advisory committee to the US Food and Drug Administration (FDA) voted July 26 to recommend ocriplasmin (Jetrea, ThromboGenics, Inc) 125 μg intravitreal injection for the treatment of symptomatic vitreomacular adhesions (sVMAs), including macular hole.
The committee voted unanimously to recommend approval of ocriplasmin for the treatment of VMAs, and 7 to 3 in favor of recommending approval for treatment of macular holes. "I thought the anatomic data was very favorable," Stephen S. Feman, MD, MPH, a professor at Saint Louis University School of Medicine in Missouri and voting committee member, said during the advisory meeting.
Symptomatic VMAs result from incomplete separation of the vitreous from the macula and can be progressive and result in blindness. At this time, the only treatment option is vitrectomy, a major surgical procedure that is usually postponed until late in the disorder because of the potential risks and difficult recovery period. Ocriplasmin is the first pharmacologic treatment for symptomatic VMAs and could improve outcomes by making treatment available earlier.
Ocriplasmin is a recombinant truncated form of the human serine protease plasmin with retained enzymatic activity that acts on collagen, fibronectin, and laminin to liquefy the vitreous, resulting in its detachment from the macula.
The committee discussed data from 2 randomized, phase 3, placebo-controlled studies, TG-MV-006 and TG-MV-007. Each study had 326 participants, and a total of 652 eyes were injected.
The studies enrolled patients with sVMA, which was described as vitreomacular traction with or without a full-thickness macular hole.
Patients were seen for 7 visits during a 6-month period: at baseline and on injection day (day 0), postinjection day 7, postinjection day 14, postinjection day 28, postinjection month 3, and postinjection month 6.
Efficacy
The primary efficacy endpoint was the proportion of patients whose focal VMA resolved without surgery at day 28 postinjection, as determined by masked central reading center optical coherence tomography evaluation.
The secondary efficacy endpoint was the proportion of patients who had total posterior vitreous detachment at day 28, as determined by masked investigator assessment of B-scan ultrasound.
Primary endpoints were achieved in each study, and statistically significantly higher VMA resolution rates were seen at day 28 in patients who received a single injection of 125 μg ocriplasmin compared with placebo.
In study TG-MV-006, 13.1% (n = 107) of patients who received placebo and 27.9% (n = 219) of patients who received ocriplasmin met primary efficacy endpoints.
In study TG-MV-007, 6.2% (n = 81) of patients who received placebo and 25.3% (n = 245) of patients who received ocriplasmin met primary efficacy endpoints.
Safety
Data from a total of 7 completed studies, including TG-MV-006 and TG-MV-007, also were analyzed for safetyas well. Of note, 9 of 976 ocriplasmin-treated patients experienced temporary, postinjection serious and/or severe adverse events that involved acute vision decrease within 24 hours of injection. Vision returned to at least pretreatment levels (median time, 2 weeks) in all but 1 patient, whose vision decrease was considered to be related to concurrent retinal disease. The reasons for this are unclear.
A total of 8 patients from the 7 studies died; 6 were in the treatment group and 2 were in the placebo group. None of the deaths were related to treatment.
"The majority of patients who receive this drug will not get benefit from the drug, and I think that that needs to be very clearly stated. If the drug is approved, it must be very clearly stated in labeling.... Even though there is efficacy benefit over risk...the majority of patients will not see a benefit from this drug," said Lynn Gordon, MD, PhD, a professor of ophthalmology at Jules Stein Eye Institute and associate dean of diversity affairs at David Geffen School of Medicine at the University of California, Los Angeles, and voting committee member, said during the advisory meeting.
"I agree with [Dr. Gordon's] concerns, but I suspect that the sponsor will look at, and the ophthalmology community will identify, which patients have a higher potential for benefit with this treatment," said Susan MacDonald, MD, director of comprehensive ophthalmology and assistant professor at Tufts University School of Medicine, Boston, Massachusetts, also a voting committee member, said during the advisory meeting.
"I believe that if you can reduce the number of people that need vitrectomy by 25% by using this medication, you're really making a benefit to mankind," said Dr. Feman.
No relevant financial relationships were disclosed by the voting committee members. The industry representative is employed by Forest Laboratories.

Comments

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more